News Conference News HRS 2025 GLP-1 Drugs May Have Role in Secondary Prevention of AF Todd Neale April 28, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Conference News ACC 2025 FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints L.A. McKeown April 03, 2025
News Conference News ACC 2025 Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP Michael O'Riordan April 01, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients Michael O'Riordan March 26, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Daily News CV Screening, Care at UK Football Club Made Inroads Against HF Caitlin E. Cox March 07, 2025
News Daily News Patchy Anticoagulation Use During COVID Pandemic Raises Questions L.A. McKeown March 06, 2025
News Daily News Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF Michael O'Riordan March 03, 2025
News Daily News Patient-Centric Outcomes Embraced by Global Heart Valve Experts L.A. McKeown February 24, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time Michael O'Riordan February 13, 2025
News Daily News CVD Hospitalization in Older Adults Higher in US Than in Denmark Michael O'Riordan February 07, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Mental Stress Score May Pinpoint Stable CAD Patients at Risk for CV Events L.A. McKeown January 28, 2025
News Daily News DRIVE-STEMI Supports Less Restrictive Driving Guidance After Acute MI L.A. McKeown January 23, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025